Cleveland BioLabs, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Cleveland BioLabs, Inc. (“BioLabs” or the “Company”) (NASDAQ: CBLI) with Cytocom, Inc. (“Cytocom”). Under the terms of the merger, BioLabs stockholders will control only 39% of the combined company.

The BioLabs merger investigation concerns whether the Board of BioLabs has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.